Health Care·Biotechnology·$5.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.56 | N/A | -9.70% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.56 | N/A | -9.70% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide specific guidance for the upcoming quarters.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current challenges.
This earnings report indicates that Apellis Pharmaceuticals is facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 0.76%, likely due to investor concerns over the lack of guidance and the ongoing financial performance. The absence of revenue figures adds to the uncertainty surrounding the company's current standing.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023